Browse articles from EyeWorld.org related to IOLs. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ FDA accepts NDA for ‘first-of-its-kind’ anti-inflammatory for dry eye ➤ Positive Phase 3 results for investigational presbyopia therapy ➤ Study: long-term visual outcomes with remote monitoring technology ➤ Companies partner to create tool to assess fall risk ➤ ASCRS news and events
➤ FDA approves new therapy for amblyopia ➤ First-in-human data from IOL/drug-delivery platform ➤ Largest crosslinking study to date for keratoconus ➤ Interim data for Phase 2 trial evaluating choroidal melanoma treatment ➤ Gene therapy update ➤ SLT trial seeking more clinical sites, deadline October 14 ➤ Acquisition news ➤ ASCRS news and events
➤ FDA approves new ocular surface anesthesia gel ➤ New drop approved to reduce IOP ➤ Newly available IOL incorporates technology that minimizes visual disturbances ➤ Interim data from Phase 1 trial for intravitreal implant to treat AMD ➤ Multiparty financing solution brought to ophthalmic practices ➤ Complimentary access to video journal ➤ ASCRS news and events
The Weill Cornell ophthalmology residents reviewed “Real-world incidence of monofocal toric intraocular lens repositioning: analysis of the American Academy of Ophthalmology IRIS Registry” from the Journal of Cataract & Refractive Surgery.
Corneal imaging for IOL planning is vital, but what instruments to use and what the measurements from these different instruments inform varies. EyeWorld spoke with two physicians to get their thoughts on corneal imaging as part of the preop planning process.
➤ Autologous stem cell therapy to treat dry AMD ➤ Topline results from Phase 3 trial for GA therapy ➤ Update on Phase 3 myopia progression clinical trial ➤ FDA accepts NDA application for investigational dry eye therapy ➤ ASCRS news and events
➤ New device for bladeless goniotomy ➤ FDA approves the first at-home digital vision test ➤ Alcon to acquire Aerie Pharmaceuticals ➤ Study: Phase 2 trial for investigational dry eye therapy meets primary endpoint ➤ ASCRS news and events
➤ Long-term safety, efficacy data reported from standalone MIGS procedure ➤ Positive clinical data in ongoing trial for investigational thyroid eye disease treatment ➤ Bioengineered cornea restores vision in 20 people ➤ ASCRS news and events
➤ FDA approves new multifocal IOL ➤ FDA approves new biosimilar ➤ First patient dosed in Phase 3 trial for investigational dry eye drug ➤ First patient dosed in Phase 2 trial investigating sustained delivery for wet AMD ➤ First patient dosed in Phase 2 study of small molecule to treat diabetic retinopathy ➤ Enrollment complete in Phase 3 trials evaluating myopia progression therapy ➤ Study emphasizes need for earlier glaucoma screening in black patients ➤ Company acquires diagnostic technology ➤ ASCRS news and events
➤ 12-month Phase 1 trial data from sustained drug delivery option for anti-VEGF therapy ➤ Phase 1b results for possible topical treatment of corneal injuries ➤ Long-term safety and efficacy reinforced with 2-year clinical trial data of AMD therapy ➤ FDA accepts NDA for GA therapy ➤ NDA submitted for investigational dry eye treatment ➤ Company completes guidance meeting with FDA for dry eye drug ➤ Companies partner to conduct Phase 3 trials for possible NK treatment ➤ Partnership to develop gene therapy ➤ ASCRS news and events